(Q30379228)

21 June 2017

1 reference

1 reference

title

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. (English)

1 reference

21 June 2017

1 reference

1 reference

2

0 references

John Ioannidis

5

object named as

John P A Ioannidis

0 references

Lamberto Manzoli

object named as

Lamberto Manzoli

1

0 references

author name string

Corrado De Vito

3

1 reference

21 June 2017

Antonio Boccia

4

1 reference

21 June 2017

Paolo Villari

6

1 reference

21 June 2017

publication date

1 August 2009

1 reference

Lancet Infectious Diseases

21 June 2017

published in

1 reference

21 June 2017

volume

9

1 reference

21 June 2017

issue

8

1 reference

21 June 2017

page(s)

482-492

1 reference

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

How prepared is Europe for pandemic influenza? Analysis of national plans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Vaccines against avian influenza--a race against time

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Confronting the avian influenza threat: vaccine development for a potential pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Development of vaccines against influenza H5

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

H5N1 vaccines: how prepared are we for a pandemic?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Exploring the geometry of treatment networks.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Uncertainty in heterogeneity estimates in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Inactivated whole virus influenza A (H5N1) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Mechanism of action of licensed vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Seasonal and pandemic influenza: a 2007 update on challenges and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Towards a sane and rational approach to management of Influenza H1N1 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Human infection with highly pathogenic H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and direct

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970153-7

7 January 2021

10.1016/S1473-3099(09)70153-7

Identifiers

DOI

1 reference

21 June 2017

1 reference